539 results on '"Yamashita T"'
Search Results
2. Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
3. Maneuvering simulations at large drift angles of a ship with a flapped rudder
4. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
5. Impact of pre-operative cachexia and sarcopenia on post-operative physical function and skeletal muscle mass in lung cancer patients
6. P156 Usefulness of pretreatment 1CTP levels as prognosis prediction
7. How much experience is required to acquire the skills for spinal surgery? Results of a survey of spinal surgeons
8. Risk factors of decrease of locomotive ability after osteoporotic vertebral fractures
9. Investigation of the therapeutic efficacy of bone marrow mesenchymal stem cells for neuropathic pain
10. Analysis of clinical features of concomitant spine and joint infections
11. 85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
12. Evaluation of heat removal property in W/Cu/RAFM steel joint by using electron beam facility
13. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
14. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
15. Different changes in the biomarker C-terminal telopeptides of type II collagen (CTX-II) following intra-articular injection of high molecular weight hyaluronic acid and oral non-steroidal anti-inflammatory drugs in patients with knee osteoarthritis: a multi-center randomized controlled study
16. 62P Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small cell lung cancer patients
17. 309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
18. 279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
19. 937P Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
20. 954P Comparison of medical costs and outcome between hepatectomy and radiofrequency ablation for hepatocellular carcinoma
21. Development of the brazing technique of W and JLF-1 by Ni-P filler material
22. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
23. Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
24. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
25. LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
26. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
27. 138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses
28. A Rare Case of Pyogenic Spondylitis Caused by Aggregatibacter Actinomycetemcomitans
29. Outcomes Following Synchronous Resection Of Colorectal Cancer Primary And Liver Metastases
30. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
31. Neuroprotective therapy both for als and acute ischemic stroke
32. A rapid screening method for CADASIL by means of dot blot analyses using biopsied skin samples
33. A temporal change of in vivo oxidative stress imaging in a mouse stroke model
34. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
35. Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
36. P.337Dystrophin restoration by exon 53 skipping in patients with Duchenne muscular dystrophy after viltolarsen treatment: phase 2 study update
37. Alpelisib (ALP) + fulvestrant (FUL) for patients with hormone receptor–positive (HR+), HER2− advanced breast cancer (ABC): Management and time course of key adverse events of special interest (AESIs) in SOLAR-1
38. Alpelisib (ALP) + fulvestrant (FUL) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial
39. Re-sentinel node biopsy for local recurrence after breast-conserving surgery
40. First-in-Human Phase I Study of a Non-Woven Fabric Bioabsorbable Spacer Combined with Particle Therapy Against Abdominal or Pelvic Sarcomas
41. 282 Giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi in a patient with mosaic neurofibromatosis type 1 caused by biallelic NF1 microdeletions
42. Phospholipid distributions in purple phototrophic bacteria and LH1-RC core complexes
43. Coordinated existence of multiple gangliosides is required for cartilage metabolism
44. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
45. Indications for partial parotidectomy using retrograde dissection of the marginal mandibular branch of the facial nerve for benign tumours of the parotid gland
46. Influence of tongue composition change on tongue pressure in the elderly: A study using tongue MR imaging with Dixon
47. The effect of Balance Exercise Assist Robot (BEAR) to patient after allogenetic hematopoietic stem cell transplantation (allo-HSCT): Preliminary study
48. Characterization of double Shockley-type stacking faults formed in lightly doped 4H-SiC epitaxial films
49. Effectiveness of Neo-Adjuvant Systemic Therapy for Basal HER2 type Breast Cancer – Results from Retrospective Cohort Study of Japan Breast Cancer Research Group (JBCRG) – C03
50. Singularities of tangent surfaces to directed curves
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.